ArticleCell reports2021
Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies.Frontiers in immunology · 2022Pooled it
- Genetic and non-genetic factors distinctly shape the variation of the immune response in cattle.Nature communications · 2026Article
- Distinct pro-inflammatory/pro-angiogenetic signatures distinguish children with Long COVID from controls.Pediatric research · 2025Article
- Assessing the Value of T cell Monitoring in the General Population of Children and Adolescents - Insights From the Ciao Corona Cohort Study.International journal of public health · 2025Observational
- Potential Immune-Inflammatory Proteome Biomarkers for Guiding the Treatment of Patients with Primary Acute Angle-Closure Glaucoma Caused by COVID-19.Journal of proteome research · 2024Article
- Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection.Scientific reports · 2024Article
- Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivity.iScience · 2024Article
- Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2.Diseases (Basel, Switzerland) · 2024Article
- Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents.BMC infectious diseases · 2023Article
- Susceptibility of SARS-CoV2 infection in children.European journal of pediatrics · 2023Review
- Comparative Immune Response after Vaccination with SOBERANAVaccines · 2023Article
- Long-term humoral signatures following acute pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.Pediatric research · 2023Article
- Understanding COVID-19 in children: immune determinants and post-infection conditions.Pediatric research · 2023Review
- The Immunological Profile of SARS-CoV-2 Infection in Children Is Linked to Clinical Severity and Age.International journal of molecular sciences · 2023Article
- A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant.Plant biotechnology journal · 2023Article
- The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups.Pathogens (Basel, Switzerland) · 2023Review
- A single-cell atlas reveals shared and distinct immune responses and metabolic profiles in SARS-CoV-2 and HIV-1 infections.Frontiers in genetics · 2023Article
- Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection.JAMA network open · 2022Article
- Immunopathology of SARS-CoV-2 Infection: A Focus on T Regulatory and B Cell Responses in Children Compared with Adults.Children (Basel, Switzerland) · 2022Article
- COVID-19 in children: From afterthought to unknown.Cell reports. Medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 6 institutions in 2 countries.
Nicola CotugnoAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata," 00185 Rome, Italy.
Alessandra RuggieroAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Francesco BonfanteLaboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, 35020 Legnaro, Italy.
Maria Raffaella PetraraSection of Oncology and Immunology, Department of Surgery, Oncology, and Gastroenterology, Unit of Viral Oncology and AIDS Reference Center, University of Padova, 35128 Padova, Italy.
Sonia ZicariAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Giuseppe Rubens PascucciAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Paola ZangariAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Maria Antonietta De IorisAcademic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Veronica SantilliAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
E C MannoAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Donato AmodioAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata," 00185 Rome, Italy.
Alessio BortolamiLaboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, 35020 Legnaro, Italy.
Matteo PagliariLaboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, 35020 Legnaro, Italy.
Carlo ConcatoDepartment of Laboratories, Division of Virology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Giulia LinardosDepartment of Laboratories, Division of Virology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Andrea CampanaAcademic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Daniele DonàDepartment of Mother and Child Health, University of Padova, 35128 Padova, Italy.
Carlo GiaquintoDepartment of Mother and Child Health, University of Padova, 35128 Padova, Italy.
CACTUS Study Team
Petter BrodinPediatric Rheumatology, Karolinska University Hospital, 17177 Stockholm, Sweden.
Paolo RossiAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata," 00185 Rome, Italy.
Anita De RossiSection of Oncology and Immunology, Department of Surgery, Oncology, and Gastroenterology, Unit of Viral Oncology and AIDS Reference Center, University of Padova, 35128 Padova, Italy; Istituto Oncologico Veneto (IOV)-IRCCS, 35128 Padova, Italy.
Paolo PalmaAcademic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata," 00185 Rome, Italy. Electronic address: paolo.palma@opbg.net.
Bambino Gesù Children's Hospital · ITUniversity of Padua · ITUniversity of Rome Tor Vergata · ITIstituto Zooprofilattico Sperimentale delle Venezie · ITKarolinska University Hospital · SEIstituto Oncologico Veneto · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the global COVID-19 pandemic progresses, it is paramount to gain knowledge on adaptive immunity to SARS-CoV-2 in children to define immune correlates of protection upon immunization or infection. We analyzed anti-SARS-CoV-2 antibodies and their neutralizing activity (PRNT) in 66 COVID-19-infected children at 7 (±2) days after symptom onset. Individuals with specific humoral responses presented faster virus clearance and lower viral load associated with a reduced in vitro infectivity. We demonstrated that the frequencies of SARS-CoV-2-specific CD4
Indexed as
Adaptive ImmunityAntibodies, NeutralizingAntibodies, ViralB-LymphocytesCD4-Positive T-LymphocytesChildCOVID-19HumansImmunity, HumoralProteomeSARS-CoV-2Signal TransductionViral LoadAntibodies, NeutralizingAntibodies, ViralProteomeAb-mediated neutralization activityantigen-specific B cellsantigen-specific CD4 T cellsanti-SARS-CoV-2 antibodiesCOVID-19pediatric COVID-19proteomic profilingSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.